Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. MaxCyte, Inc.
  6. News
  7. Summary
    MXCT   US57777K1060

MAXCYTE, INC.

(MXCT)
  Report
Delayed London Stock Exchange  -  04:08:10 2023-02-06 am EST
480.00 GBX   +1.05%
02/01MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences
GL
01/30TRADING UPDATES: DP Eurasia annual sales grow despite Russia decline
AN
01/25Capitalgainsreport : Biotech Stocks To Watch in 2023: PBIO, BYSI, NRSN, MXCT, OSUR
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MAXCYTE, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

12/01/2022 | 08:32am EST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Patrick Balthrop as Director

On November 30, 2022, upon the recommendation of its Nominating and Corporate Governance Committee (the "Nominating Committee"), the Board of Directors (the "Board") of MaxCyte, Inc. (the "Company") appointed Patrick J. Balthrop, Sr. to serve as a Class II director. Mr. Balthrop will serve for the term expiring at the Company's 2023 annual meeting of stockholders, and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal. Mr. Balthrop was also appointed as a member of the Nominating Committee. Mr. Balthrop was not selected as a director pursuant to any arrangements or understandings with the Company or with any other person.

Mr. Balthrop, 66, has more than three decades of experience in the healthcare sector, particularly in diagnostics, life science tools and medical devices. From 2004 until his retirement in 2014, Mr. Balthrop was President, Chief Executive Officer and a director of Luminex Corporation, a publicly held life science tools and molecular diagnostics company. From 2002 to 2004, he served as president of Fisher Healthcare, now a division of Thermo Fisher Scientific, Inc. He previously served for more than 20 years in roles of increasing responsibility with Abbott Laboratories, including as head of Abbott Vascular and Corporate VP of Worldwide Operations for Abbott Diagnostics. He currently serves as chairman of the board of the privately held life sciences companies Agendia, Inc. and Diagnostic Life Sciences and as director of the privately held life sciences company Pattern Biosciences. Within the past five years, he served as a director of the publicly held diagnostics company Oxford Immunotec Global PLC, including as its chairman from June 2019 until March 2021. He has also served as a member of the board of directors of Personalis, Inc., a publicly held cancer genomics company, from 2015 until March 2021. In January 2015, Mr. Balthrop founded and has since served as Principal of Apalachee Ventures, LLC, an investment and advisory firm. He also serves as executive advisor to Water Street Healthcare Partners, a healthcare-focused private equity firm. Mr. Balthrop holds a B.S. in Biology from Spring Hill College and an M.B.A. from the Kellogg School of Management at Northwestern University.

Upon his commencement of service as a director, Mr. Balthrop was granted a nonqualified stock option to purchase 100,000 shares of the Company's common stock with an exercise price of $5.99 per share, which was the closing price of the Company's common stock on the Nasdaq Global Market on the date of grant. This option will vest and become exercisable over three years, with one-third of the shares vesting after 12 months, and the remainder vesting monthly over the following 24 months until the third anniversary of the date of grant, subject to Mr. Balthrop's continuous service, as defined in the Company's 2022 Equity Incentive Plan (the "Plan"), through each applicable vesting date. Additionally, Mr. Balthrop will be entitled to receive a $40,000 annual retainer for his service as a director and a $5,000 annual retainer as a member of the Nominating Committee.

The Company intends to enter into its standard form of indemnification agreement with Mr. Balthrop, the form of which was filed as Exhibit 10.8 to Amendment No. 1 to the Company's Registration Statement on Form S-1, which was filed with the Securities and Exchange Commission on July 26, 2021.

There are no related party transactions between Mr. Balthrop and the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no family relationships between Mr. Balthrop and any director or executive officer of the Company.

Item 7.01 Regulation FD Disclosure.

On December 1, 2022, the Company issued a press release announcing the appointment of Mr. Balthrop as a director of the Company. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit
 No.       Description

  99.1       Press Release dated December 1, 2022
104        Cover Page Interactive Data (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses

All news about MAXCYTE, INC.
02/01MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023..
GL
01/30TRADING UPDATES: DP Eurasia annual sales grow despite Russia decline
AN
01/25Capitalgainsreport : Biotech Stocks To Watch in 2023: PBIO, BYSI, NRSN, MXCT, OSUR
AQ
01/05Insider Sell: Maxcyte
MT
01/05Insider Sell: Maxcyte
MT
01/05MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell ..
AQ
01/04MaxCyte signs strategic platform licence with Catamaran Bio
AN
01/04MaxCyte Licenses Cell-based Platform Technologies to Catamaran Bio
MT
01/03MaxCyte Signs License Agreement With Catamaran Bio; Shares Jump After Hours
MT
01/03MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell ..
GL
More news
Analyst Recommendations on MAXCYTE, INC.
More recommendations
Financials (USD)
Sales 2022 44,9 M - -
Net income 2022 -25,4 M - -
Net cash 2022 227 M - -
P/E ratio 2022 -23,1x
Yield 2022 -
Capitalization 591 M 591 M -
EV / Sales 2022 8,12x
EV / Sales 2023 6,72x
Nbr of Employees 84
Free-Float 94,1%
Chart MAXCYTE, INC.
Duration : Period :
MaxCyte, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MAXCYTE, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 5,74 $
Average target price 11,96 $
Spread / Average Target 108%
EPS Revisions
Managers and Directors
Douglas A. Doerfler President, Chief Executive Officer & Director
Ronald E. Holtz Senior VP, Chief Financial & Accounting Officer
Richard H. Douglas Independent Chairman
James Brady VP-Technical Applications & Customer Support
Cenk Sumen Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
MAXCYTE, INC.8.57%591
THERMO FISHER SCIENTIFIC6.73%231 606
DANAHER CORPORATION1.67%196 532
INTUITIVE SURGICAL, INC.-4.02%90 000
BOSTON SCIENTIFIC CORPORATION4.82%69 467
SIEMENS HEALTHINEERS AG15.64%65 645